trending Market Intelligence /marketintelligence/en/news-insights/trending/SeR00TMUaRmwUTCGyJgchA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Equistone to buy majority stake in German pharmaceutical wholesaler Omnicare

Street Talk Episode 56 - Latest bank MOE shows even the strong need scale to thrive

South State CenterState MOE Shows Even The Strong Need Scale To Thrive

Talking Bank Stocks, Playing The M&A Trade With Longtime Investor

Report: Kashkari Says Fed In Holding Pattern But Rate Cut Still Possible

Equistone to buy majority stake in German pharmaceutical wholesaler Omnicare

Equistone Partners Europe Ltd. is purchasing a majority stake in German pharmaceutical wholesaler Omnicare Pharma GmbH for an undisclosed amount.

The outpatient oncology care platform is being sold by a shareholder consortium that will continue to own a stake in the company.

Omnicare Managing Director Oliver Tamimi will continue to lead the company. The deal is set to close in the fourth quarter, subject to competition authority approvals.

Equistone was advised by P+P on legal and tax, Alvarez & Marsal on commercial, Deloitte on financial, Houlihan Lokey on financing, Dechert on trust, Shearman & Sterling on legal financing, and ETS on insurance matters.

Omnicare's management team was advised by Hengeler Müller on legal and trust, BCG on commercial, KPMG on financial, EY on tax, Lincoln International on mergers and acquisitions, and Honert & Partner on MEP.